Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Clinical trial NCT05778149 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05778149
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Aumolertinib Anlotinib TP53 NSCLC EGFR Activating Mutation

Start date: 2023-03-31
Primary completion: 2025-03-31
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.